The safety of Sildenafil products such as Silagra 100 mg is monitored through multiple layers of drug regulation and pharmacovigilance systems. In India, the main authority responsible is the Central Drugs Standard Control Organization, headed by the Drug Controller General of India (DCGI). This body approves medicines, sets safety standards, and can issue warnings, restrictions, or bans if serious risks are identified. Ongoing safety monitoring is carried out by the Pharmacovigilance Programme of India, which collects and analyzes reports of side effects from doctors, hospitals, and patients across the country. These reports help detect rare or long-term adverse reactions. The manufacturer of Silagra (Cipla) is also legally required to monitor product safety, report adverse drug reactions, and maintain quality control during production. Globally, organizations like the World Health Organization support drug safety monitoring through international reporting databases and coordination between countries.